Ozmosi | Afuresertib Drug Profile

Product Description

Afuresertib is a reversible, ATP-competitive, oral, low-nanomolar, pan-AKT kinase inhibitor. (Sourced from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4229853/)

Mechanisms of Action: Akt Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Laekna
Company Location: Asia Pacific
Company CEO:
Additional Commercial Interests: Novartis

Clinical Description

Map of Global Clinical Trials for Afuresertib

Countries in Clinic: China, Korea, United States

Active Clinical Trial Count:

Recent & Upcoming Milestones

Highest Development Phases

Phase 3: Breast Cancer

Phase 1: Triple Negative Breast Cancer

Trial ID	Trial	Phase	Trial Status	Disease	Primary Completion Date	Probability of Success	Latest Trial Update Date	Data Updated
NCT05390710	LAE203CN2101	P1	Completed	Triple Negative Breast Cancer	2023-12-11	35%	2024-02-01	Patient Enrollment\|Primary Completion Date\|Primary Endpoints\|Study Completion Date\|Treatments\|Trial Status
CTR20202361	CTR20202361	P2	Completed	Ovarian Cancer\|Fallopian Tube Cancer\|Peritoneal Cancer	2024-02-26		2025-04-29	Patient Enrollment\|Primary Completion Date\|Study Completion Date\|Treatments\|Trial Status
NCT04060394	LAE201INT2101	P2	Completed	Prostate Cancer	2023-12-27	20%	2024-08-20
NCT04374630	PROFECTA-II	P2	Completed	Ovarian Cancer	2023-07-31	47%	2024-08-20	Patient Enrollment\|Primary Endpoints
NCT04851613	LAE205INT3101	P3	Recruiting	Breast Cancer	2026-10-30	31%	2025-09-17
NCT05383482	LAE202CN2101	P2	Completed	Cervical Cancer\|Non-Small-Cell Lung Cancer\|Adenocarcinoma\|Gastrointestinal Cancer\|Uterine Cancer\|Endometrial Cancer\|Small Cell Lung Cancer\|Esophageal Cancer	2024-06-25	26%	2025-11-18	Primary Endpoints\|Start Date\|Study Completion Date\|Treatments\|Trial Status
CTR20213426	CTR20213426	P1	Completed	Breast Cancer	2024-11-28		2025-04-29	Patient Enrollment\|Primary Completion Date\|Start Date\|Study Completion Date\|Treatments\|Trial Status
CTR20253540	CTR20253540	P1	Recruiting	Breast Cancer	None		2025-10-21
CTR20253541	CTR20253541	P1	Recruiting	Breast Cancer	None		2025-10-21	Patient Enrollment\|Treatments\|Trial Status
CTR20240665	CTR20240665	P3	Active, not recruiting	Breast Cancer	None		2025-12-28	Patient Enrollment\|Treatments\|Trial Status

Recent News Events

Date	Type	Title
04/15/2025	News Article	Predictive Oncology Develops Novel Approach to Identifying Clinically Viable Abandoned Drugs
11/20/2024	News Article	Laekna Announces a Clinical Collaboration with Lilly to Develop LAE102, a Novel Monoclonal Antibody Targeting Activin Receptor Type 2A for The Treatment of Obesity
06/05/2024	PubMed	Identification of hub genes and potential therapeutic mechanisms related to HPV positive head and neck squamous carcinoma based on full transcriptomic detection and ceRNA network construction.
05/23/2024	News Article	Laekna Announces FDA Approval for the Phase III Clinical Trial Protocol of LAE002 (Afuresertib) PLUS LAE001 for the Treatment of Prostate Cancer
04/29/2024	News Article	Laekna Releases 2023 ESG Report
02/18/2024	PubMed	Bulk and single-cell sequencing identified a prognostic model based on the macrophage and lipid metabolism related signatures for osteosarcoma patients.
12/28/2023	PubMed	Extensive prediction of drug response in mutation-subtype-specific LUAD with machine learning approach.

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you've used PRYZM, we hope you're able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions

Session Expiring Soon

Afuresertib

Alternative Names: afuresertib, gsk2110183, gsk-21110183, gsk 21110183, GSK21110183, GSK 21110183, GSK-21110183 Clinical Status: Active Latest Update: 2025-11-17 Latest Update Note: Clinical Trial Update